Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by fredgoodwinson on Dec 08, 2020 2:11pm

13 & 14

Patients 13 & 14 will be our patients 5 & 6 (i.e.optimally dosed - this time twice).

 

They may well already have 30-day data for one of them. Only 37 days` after P.6`s single treatment they were able to pronounce:

 

‘To date the patient has shown no evidence or presence of disease’ This was interpreted as them having confidence at a very early stage (correctly as it turned out) of an enduring complete response.

 

So there may well be highly price sensitive already available from these recent treatments .Whether they feel inclined or able to publish it independently from the results of the second treatments remains to be seen - probably not.

 

Even so and although statistically insignificant for many of us these two will be the acid test for the NMIBC Trial. Some time in June?

 
Comment by CancerSlayer on Dec 08, 2020 3:13pm
I know little steps are important, but the ultimate litmus test for me is having whatever amount of data that can lead to a breakthrough therapy designation.  Considering additional data from our Covid-19 & Roswell research teams continue to shine, such a designation would "seriously" trigger Big Pharma interest, not to mention possibly decrease trial time by "another" ...more  
Comment by Johnandrose22 on Dec 08, 2020 3:20pm
Agree’d....at this point, the results of treatment for patients 13 and 14 ( non mistake and optimized) will be the line in the sand not only for the NMIBC trial but for the future of this company. 
Comment by enriquesuave on Dec 08, 2020 3:21pm
I agree there Fred.  If they have enrolled a few more in December (1 per site would be another 4 patients and would be awesome), then we could see some data perhaps fairly early next year on all patients who have reached reached 3 months and for 1st set 9 months data point.  Even after 30 days with P5 and 6 from PH1, they knew they had good results IMo, as urine cytology was probably ...more  
Comment by menoalittle on Dec 08, 2020 6:34pm
>>  That is 42 times, with the right data anything goes.  I've had a few 10 baggers... but never a "100 bagger." Am thinkin' (...okay, call it dreamin' if you want) this one might be the first one. (And would be plenty happy enough if it were the last.  Namely  'cause I wouldn't ever need another one... lol.)
Comment by CancerSlayer on Dec 08, 2020 9:31pm
Agree Enrique.  Our big pharma antagonist may just be our US clinical trial impetus with their timely vaccine trial success.  Many US hospitals now have their sub-zero fridges in house, plugged in & ready for cold storage.  We should be getting two EUA approvals in the next week, then it will be state/county health departments coordinating the vaccine rollouts to all frontline ...more  
Comment by Rumpl3StiltSkin on Dec 09, 2020 8:26am
Encouraging news! TLT should have the necessary numbers of enrolled patients for FDA Accelerated Approval soon. 
Comment by Oden6570 on Dec 09, 2020 8:54am
Look we still have covid so it will continue to hold us back. Ontario, Quebec, BC hospitals backlogged already with elective surgery. The East Coast is doing well so perhaps we could fly patients in for treatment, oh I forgot Airlines are cancelling service to the east coast province's.
Comment by floatinketucky on Dec 09, 2020 9:06am
The company is treating new patients and signing up more hospitals. The company is moving forward. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250